Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E23.39 EPS (ttm)4.12 Insider Own0.10% Shs Outstand1.60B Perf Week2.19%
Market Cap153.77B Forward P/E14.65 EPS next Y6.57 Insider Trans-30.42% Shs Float1.59B Perf Month1.64%
Income6.62B PEG1.54 EPS next Q1.44 Inst Own72.00% Short Float0.95% Perf Quarter10.22%
Sales27.27B P/S5.64 EPS this Y15.60% Inst Trans1.63% Short Ratio2.45 Perf Half Y35.54%
Book/sh4.19 P/B22.98 EPS next Y18.37% ROA9.90% Target Price99.85 Perf Year56.15%
Cash/sh5.98 P/C16.10 EPS next 5Y15.21% ROE118.50% 52W Range59.27 - 98.87 Perf YTD53.78%
Dividend2.84 P/FCF34.59 EPS past 5Y10.80% ROI18.00% 52W High-2.60% Beta1.54
Dividend %2.95% Quick Ratio1.30 Sales past 5Y8.00% Gross Margin76.50% 52W Low62.48% ATR1.95
Employees29000 Current Ratio1.50 Sales Q/Q8.80% Oper. Margin37.20% RSI (14)55.68 Volatility1.98% 1.91%
OptionableYes Debt/Eq5.65 EPS Q/Q4.40% Profit Margin24.30% Rel Volume0.64 Prev Close97.35
ShortableYes LT Debt/Eq5.08 EarningsJan 26 BMO Payout60.20% Avg Volume6.19M Price96.30
Recom2.30 SMA201.13% SMA502.80% SMA20025.64% Volume3,937,051 Change-1.08%
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Dec-14-17 06:02AM  Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors Motley Fool
Dec-13-17 07:15AM  Roche/AbbVie Report Positive Phase III Results on Venclexta Zacks
Dec-12-17 09:00PM  AbbVie Makes Progress on Quest to Diversify Motley Fool
06:04PM  Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug Zacks
05:39PM  Novartis Announces Positive Data on Sickle Cell Disease Drug Zacks
09:00AM  How Is Olumiant Positioned after 3Q17? Market Realist
07:30AM  AbbVie Announces Phase 3 Study of VENCLEXTA/ VENCLYXTO (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint PR Newswire
Dec-11-17 04:26PM  These 5 Top Stocks Are Near Buys In This Bullish Pattern: Action Plan Investor's Business Daily
10:27AM  This Is How To Invest in the Marijuana Industry Insider Monkey
10:00AM  IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition PR Newswire
Dec-10-17 09:07AM  Better Buy: Pfizer (PFE) vs. AbbVie (ABBV) Motley Fool
Dec-09-17 12:00PM  IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) PR Newswire
09:00AM  IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients PR Newswire
Dec-08-17 09:57AM  Why Biotech Stocks May Wait A While Before Feeling The Love Investor's Business Daily
Dec-06-17 04:50PM  Top 5 Biotech Stocks for 2017 Investopedia
11:35AM  Janssen, AbbVie"s Imbruvica Achieves PFS in Innovate Study GuruFocus.com
08:52AM  AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan Zacks
08:01AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
07:46AM  Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data Zacks
Dec-05-17 04:04PM  Top Biotech Stock Near Buy Zone, Shows Positive Drug Trial Results Investor's Business Daily
11:24AM  True Leaf Seeks to Raise Capital as It Prepares to Enter into the Booming Canadian Marijuana Market Insider Monkey
09:52AM  AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study Zacks
08:00AM  IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint PR Newswire
Dec-04-17 10:18AM  Top 4 Marijuana Stocks to Watch Investopedia
09:11AM  Lilly's (LLY) Taltz Gets Approval for Label Expansion in US Zacks
08:12AM  AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment MarketWatch
08:03AM  Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study PR Newswire
Dec-03-17 09:09AM  5 Top Biotech Stocks to Buy Now Motley Fool
Dec-01-17 10:21AM  ETFs with exposure to AbbVie, Inc. : December 1, 2017 Capital Cube
09:01AM  How Is Pfizers Immunology and Inflammation Portfolio Positioned Now? Market Realist
07:31AM  Reading Eli Lillys Latest Developments after 3Q17 Market Realist
Nov-30-17 10:17AM  AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why Zacks
09:48AM  The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt Zacks
Nov-29-17 04:12PM  Top Research Reports for Amazon, AbbVie & Biogen Zacks
02:50PM  12 Best Dividend Stocks for the Next 12 Months InvestorPlace
09:07AM  How Do Analysts See AbbVie Inc (ABBV) Performing Over The Next Year? Simply Wall St.
08:42AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
Nov-28-17 08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Visa, The Kraft Heinz, AbbVie, Fossil Group, Geron, and Universal Insurance Holdings New Research Emphasizes Economic Growth GlobeNewswire
Nov-27-17 11:32AM  U.S. Supreme Court divided over legality of patent reviews Reuters
Nov-24-17 09:15PM  Abbvie Inc (ABBV) Chairman of the Board and CEO Richard A Gonzalez Sold $20.5 million of Shares GuruFocus.com
11:24AM  3 Companies Competing to Gain Lead in Ovarian Cancer Market Zacks
08:38AM  Will New Drug Approvals Boost Novartis (NVS) Portfolio? Zacks
Nov-23-17 09:00AM  Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Insider Monkey
Nov-21-17 09:32AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson Motley Fool
09:26AM  Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients PR Newswire
Nov-20-17 11:21AM  ETFs with exposure to AbbVie, Inc. : November 20, 2017 Capital Cube
Nov-17-17 09:05AM  Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval Zacks
Nov-16-17 07:03PM  Cramer applauds Abbott CEO Miles White for his value crea... CNBC Videos
06:54PM  Cramer applauds Miles White, Abbott CEO CNBC Videos
06:34PM  Cramer applauds Abbott CEO Miles White for his value creation and leadership CNBC
04:21PM  Endo unit cleared of liability in first testosterone replacement trial Reuters
09:44AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Nov-15-17 08:17PM  3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock Motley Fool
08:04AM  3 Stocks for Retirees to Grow Their Nest Eggs Motley Fool
07:00AM  AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference PR Newswire
Nov-14-17 02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
08:31AM  Novartis (NVS) Arm's Biosimilars Study Results Encourage Zacks
07:34AM  3 Top Big Pharma Dividend Stocks You Can Buy Right Now Motley Fool
Nov-13-17 08:57AM  Amgen Gets Positive CHMP Opinion to Expand Nplate's Label Zacks
Nov-12-17 09:37AM  3 Dividend Stocks I'd Buy Right Now Motley Fool
Nov-10-17 12:45PM  What Investors Should Know About AbbVie Incs (ABBV) Financial Strength Simply Wall St.
08:25AM  7 Things AbbVie's Top Executives Just Said That You'll Want to Know Motley Fool
Nov-09-17 11:33AM  ETFs with exposure to AbbVie, Inc. : November 9, 2017 Capital Cube
09:45AM  Republican bill would get rid of tax credits for rare disease drugs MarketWatch
08:53AM  You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018 Motley Fool
Nov-08-17 02:36PM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
Nov-06-17 03:25PM  Top 5 Biotech Stocks for 2017 Investopedia
07:31AM  Bristol-Myers Squibbs Major Developments in 3Q17 Market Realist
07:00AM  Tax Reform: A Back Door To Killing Health Care, Medicare, And More Forbes
06:02AM  5 Dividend Aristocrats With the Fastest-Growing Dividends Motley Fool
Nov-05-17 03:42AM  Edited Transcript of ABBV earnings conference call or presentation 27-Oct-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-04-17 11:08AM  These 3 Stocks Just Raised Their Dividends Motley Fool
Nov-03-17 05:06PM  Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug' Investor's Business Daily
12:57PM  AbbVie Overpromises Bloomberg
08:00AM  AbbVie to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
Nov-02-17 05:00PM  NBIX: INGREZZA® Revenues Way Ahead of Forecasts In 3Q17 Zacks Small Cap Research
10:32AM  Bristol-Myers Squibbs 3Q17 Earnings: Opdivo Market Realist
08:27AM  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate Zacks
Nov-01-17 04:28PM  Top Stock Reports for AbbVie, Union Pacific & Bristol-Myers Zacks
03:12PM  FDA Approves AstraZeneca's Blood Cancer Drug TheStreet.com
12:00PM  AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain PR Newswire
09:24AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts Zacks
08:02AM  If I Could Buy Only 1 Stock, This Would Be It Motley Fool
Oct-31-17 11:20AM  How AbbVies Drugs Performed in 3Q17 Market Realist
10:40AM  HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View Zacks
09:50AM  AbbVies Humira and Imbruvica Saw Solid Growth in 3Q17 Market Realist
08:16AM  How Did AbbVie Perform in 3Q17? Market Realist
Oct-30-17 01:52PM  Bulls pile into 2 healthcare names, a gaming stock, and a... CNBC Videos
07:30AM  Corporate News Blog - AbbVie Gets US FDA Priority Review for Elagolix for the Management of Endometriosis and Associated Pain ACCESSWIRE
Oct-29-17 09:07AM  5 Things You Need to Know From Gilead Sciences' Q3 Update Motley Fool
07:03AM  In Your 60s? 3 Stocks You Should Consider Buying Motley Fool
Oct-28-17 10:47AM  3 High-Yield Dividend Aristocrat Stocks Motley Fool
Oct-27-17 01:14PM  There's a Lot to Like in AbbVie's Q3 Update Motley Fool
12:20PM  AbbVie Inc (ABBV) Earnings: 12 Things to Know InvestorPlace
12:15PM  AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up Zacks
11:56AM  AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise Reuters
11:25AM  Dow Stock Merck, AbbVie Top Earnings Views, Light On Sales Investor's Business Daily
10:01AM  AbbVie Inc (ABBV): Immense Growth Potential? Simply Wall St.
09:58AM  Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat Zacks
09:21AM  The Biotech Blues: Gilead's Earnings Another Sour Note in a Week Full of Them Barrons.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM